glp 1 gip dual agonist mechanism of action Frontiers Mechanisms of action of GLP-1

29 GIP Agonism as a Potential Therapeutic Approach for Atherosclerotic Cardiovascular Disease The cardioprotective actions of incretin-based agents, particularly the GLP-1RAs, have a bulk of supporting evidence in the form of clinical studies

doi: 10.1016/j.jacc.2024.06.001, PMID: [DOI] [PubMed] [Google Scholar] 27

Indeed, it has been suggested that agents capable of achieving an average weight reduction of about 15% in individuals with obesity represent a new generation of anti-obesity medications, as this level of weight loss is sufficient to combat or prevent a broader range of obesity-related complications (238)

415,416,417 GLP-1RAs can exert their local effects by activating vagal dendritic terminals that innervate the gut